支气管动脉灌注化疗联合栓塞术治疗PS评分≥2分晚期NSCLC患者的临床效果  

Therapeutic effect of bronchial artery perfusion chemotherapy combined with embolization for advanced NSCLC patients with PS score≥2 points

作　　者：朱云飞 黄梦洁 刘圣斌 ZHU Yunfei;HUANG Mengjie;LIU Shengbin(不详;Department of Respiratory and Critical Care Medicine,the Second People′s Hospital of Jingdezhen,Jiangxi Province,Jingdezhen 333000,China)

机构地区：[1]江西省景德镇市第二人民医院呼吸与危重症医学科,333000 [2]江西省景德镇市第二人民医院心血管内科,333000

出　　处：《临床合理用药杂志》2024年第12期21-24,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察支气管动脉灌注化疗联合栓塞术治疗体力状况评分(PS评分)≥2分晚期非小细胞肺癌(NSCLC)患者的临床效果。方法选取2020年11月—2022年11月景德镇市第二人民医院收治的PS评分≥2分晚期NSCLC患者60例为研究对象,采用抽签法分为对照组和试验组,各30例。对照组患者接受全身静脉化疗;试验组患者接受支气管动脉灌注化疗联合栓塞术,化疗药物与对照组一致,2组21 d为1个化疗周期,持续治疗3个周期。比较2组近期疗效,治疗后症状/体征评分、PS评分、动脉血二氧化碳分压(PaCO_(2))、动脉血氧分压(PaO_(2))、第1秒用力呼气容积与用力肺活量比值(FEV_(1)/FVC)及用药不良反应。结果试验组疾病控制率(96.67%)高于对照组(73.33%)(χ^(2)=4.706,P=0.030)。治疗3个周期后,试验组咳嗽、咯痰、咯血、胸痛、阻塞性肺炎、阻塞性肺不张评分高于对照组(P<0.01);试验组PS评分为(1.08±0.42)分,低于对照组的(2.17±0.33)分(t=11.177,P<0.001);2组PaCO_(2)低于治疗前,PaO_(2)、FEV_(1)/FVC高于治疗前,且试验组降低/升高幅度大于对照组(P<0.05或P<0.01)。试验组腹泻、恶心呕吐、骨髓抑制发生率低于对照组(P<0.05)。结论支气管动脉灌注化疗联合栓塞术治疗PS评分≥2分晚期NSCLC可有效控制疾病进展,显著改善患者的临床症状及体征,改善血气及肺功能,降低不良反应发生风险,安全性较高。Objective To observe the therapeutic effect of bronchial artery perfusion chemotherapy combined with embolization for patients with advanced NSCLC with PS score≥2 points.Methods Sixty patients with advanced NSCLC with PS score≥2 points admitted to the Second People′s Hospital of Jingdezhen from November 2020 to November 2022 were selected as the subjects of this study,and the patients were divided into the control group and the experimental group by lottery method,with 30 cases in each group.Patients in the control group were received systemic intravenous chemotherapy,patients in the experimental group were received bronchial artery perfusion chemotherapy combined with embolization,and the chemotherapy drugs were the same as those in the control group.Two groups were treated with 21 days for 1 cycle of chemotherapy,and continued treatment for 3 cycles.Recent efficacy,symptom/sign score,PS score,PaCO_(2),PaO_(2),FEV_(1)/FVC,and adverse reactions of medication were compared between the two groups.Results The disease control rate of the experimental group was 96.67%,which was higher than 73.33%of the control group(χ^(2)=4.706,P=0.030).After treatment,scores of cough,sputum,hemoptysis,chest pain,obstructive pneumonia and obstructive pulmonary atelectasis in the experimental group were higher than those in the control group(P<0.01);PS score of the experimenta l group was(1.08±0.42)points,which was lower than(2.17±0.33)points of the control group(t=11.177,P<0.001);PaCO_(2)of the two groups was lower than that of pre-treatment,PaO_(2),FEV_(1)/FVC were higher than those of pre-treatment,and the decrease/increase in the experimental group were greater than those in the control group(P<0.05 or P<0.01).The incidence of diarrhea,nausea and vomiting,and bone marrow suppression in the experimental group were lower than those in the control group(P<0.05).Conclusion Bronchial artery perfusion chemotherapy combined with embolization can effectively control the disease progression in the treatment of advanced NSCLC patien

关 键 词：非小细胞肺癌 晚期 体力状况评分 支气管动脉灌注化疗 栓塞术 

分 类 号：R734.2[医药卫生—肿瘤]